Carbohydrate-deficient glycoprotein syndrome type Ie is an old name for DPM1-congenital disorder of glycosylation, often written as DPM1-CDG. It is a very rare inherited metabolic disease. In this condition, the DPM1 gene does not work properly, so the body cannot add important sugar chains to many proteins and fats in the normal way. These sugar chains help proteins fold, move, signal, and work inside the brain, muscles, eyes, liver, and other organs. Because glycosylation happens in many parts of the body, this disease can affect many systems at the same time, especially the nervous system. [1][2][3]
Carbohydrate deficient glycoprotein syndrome type Ie is now usually called DPM1-CDG or congenital disorder of glycosylation type Ie. It is a very rare inherited disease caused by harmful changes in the DPM1 gene. This gene helps the body make and attach sugar chains to proteins and lipids. When this step does not work well, many organs can be affected, especially the brain, muscles, eyes, gut, growth, and sometimes immunity. Common problems reported in published cases include developmental delay, low muscle tone, seizures, small head size, eye problems, ataxia, neuropathy, and serious feeding or gastrointestinal trouble. There is no proven cure yet, so treatment is mainly supportive and symptom-based. [1][2][3][4]
This disorder is usually autosomal recessive. That means a child usually becomes affected only when both parents pass down one non-working copy of the DPM1 gene. The disorder is not caused by food, infection, or lifestyle. The true root cause is the inherited gene change, while the many problems seen in the child happen because abnormal glycosylation then disturbs many body processes. [1][3][4]
Another Names
Other names used for this disease include DPM1-CDG, congenital disorder of glycosylation type Ie, CDG-Ie, CDG syndrome type Ie, carbohydrate-deficient glycoprotein syndrome type 1e, and dolichol-phosphate mannose synthase subunit 1 deficiency or DPM1 deficiency. Older medical literature often used “carbohydrate-deficient glycoprotein syndrome,” but newer literature uses “congenital disorder of glycosylation.” [2][5]
Types
There is no widely accepted large subtype list for DPM1-CDG itself in the way some common diseases have subtypes. Doctors usually describe it in three practical ways: old name CDG-Ie, new name DPM1-CDG, and clinical severity forms such as milder neurologic disease, classic infantile multisystem disease, or severe early-onset disease with major neurologic involvement. These are descriptive clinical patterns, not separate formal diseases. [1][4][6]
Causes
The main cause of carbohydrate-deficient glycoprotein syndrome type Ie is biallelic pathogenic variants in DPM1. To stay medically correct, the list below gives the main genetic cause plus 19 disease mechanisms that explain how the disorder develops in the body. [1][4]
1. Biallelic DPM1 gene mutations. This is the real primary cause. A child inherits two changed copies of DPM1, one from each parent, and the enzyme system does not work well enough. [1][4]
2. Autosomal recessive inheritance. The disease appears when both copies are affected, which explains why healthy carrier parents can have an affected child. [1][2]
3. Defective dolichol-phosphate mannose production. DPM1 helps make dolichol-phosphate mannose, an important sugar donor needed for normal glycosylation. [1][4]
4. Abnormal protein N-glycosylation. When the sugar donor is low, many proteins do not receive normal sugar chains, so they do not mature normally. [3][5]
5. Disturbed O-glycosylation. DPM1 problems can also disturb other glycosylation pathways, not only one pathway, which increases body-wide effects. [1][4]
6. Defective GPI-anchor synthesis. Some proteins need special anchors to stay on the cell surface. Poor glycosylation can disturb this process too. [1]
7. Poor brain cell development. The brain is very sensitive to glycosylation defects, so early brain growth and signaling can be impaired. [3][4]
8. Abnormal muscle membrane stability. DPM1 defects may reduce normal glycosylation of alpha-dystroglycan, which weakens muscle cell support. [4][7]
9. Impaired nerve signal control. Glycoproteins are important for nerve communication, so seizures and developmental problems can happen. [3][4]
10. Eye tissue involvement. Eye and visual structures also depend on normal glycosylated proteins, which helps explain frequent eye problems. [1][2]
11. Abnormal liver protein processing. The liver makes many glycoproteins. When these are not formed correctly, liver tests may become abnormal. [3][8]
12. Blood clotting protein defects. Clotting factors are glycoproteins, so some patients can develop coagulation abnormalities. [3][9]
13. Cellular transport problems. Abnormal glycosylation can change how proteins move inside cells, which harms many organs. [3][5]
14. Poor protein folding and stability. Proteins without correct sugar chains may break down early or fail to function. [3][5]
15. Reduced growth and tissue repair. Children may have poor growth because many growth-related proteins do not work normally. [2][3]
16. Early severe infantile presentation. Some variants cause very low residual function, so disease starts in the first weeks or months of life. [6][8]
17. Variant-specific severity. Different DPM1 mutations can cause different levels of enzyme loss, so some children are more severely affected than others. [6][7]
18. Multisystem metabolic stress. Because glycosylation is a basic body process, several organs can become stressed at the same time. [3][5]
19. Secondary infection vulnerability in severe cases. Very sick infants may become more fragile, and severe illness can worsen the overall course, although infection is not the root genetic cause. [6]
20. Family carrier status. A family history of carriers increases recurrence risk in future pregnancies, because the disorder is inherited. [1][2]
Symptoms
1. Developmental delay. Many children are slow to reach milestones such as head control, sitting, walking, or speaking because the brain and muscles are both affected. [1][2]
2. Severe motor delay. Movement skills may be much more delayed than expected for age, and some children show very limited motor progress. [6][8]
3. Hypotonia. Low muscle tone is common. The baby may feel floppy, have poor posture, and struggle with feeding or movement. [1][2]
4. Seizures. Many affected infants or children develop seizures, sometimes starting very early in life. [1][6]
5. Microcephaly. The head may be smaller than usual because brain growth is affected. [1][2]
6. Psychomotor retardation or global developmental impairment. This means both mental and movement development are delayed. Older papers often use this term. [2][4]
7. Eye abnormalities. Eye findings are common and may include visual defects or structural eye changes. [1][2]
8. Facial dysmorphism. Some children have unusual facial features, such as a different face shape or widely spaced eyes. [2][10]
9. Muscle weakness. Because muscle glycoproteins can be abnormal, weakness may be present in addition to low tone. [4][7]
10. Raised creatine kinase with muscle disease signs. This is a laboratory sign, but it often matches muscle injury symptoms and poor motor function. [7][8]
11. Feeding difficulty. Infants may have trouble sucking, swallowing, or gaining weight because of weakness and neurologic disease. [3][8]
12. Poor growth. Growth can be slow because of chronic illness, feeding trouble, and body-wide metabolic dysfunction. [2][3]
13. Ataxia or poor coordination. Some patients show unsteady movement or poor balance because the nervous system is involved. [4][11]
14. Peripheral neuropathy or nerve involvement. Nerve damage can contribute to weakness, reduced reflexes, or poor motor control in some glycosylation disorders, including DPM1-related disease. [3][11]
15. Liver or blood-clotting problems. Some patients show abnormal liver tests or coagulation defects, which may appear as easy bruising or abnormal blood results. [3][9]
Diagnostic Tests
Doctors usually diagnose this disorder by combining the history, exam, biochemical screening, and genetic testing. No single bedside sign is enough by itself. [3][12]
1. General physical examination. The doctor checks head size, growth, facial features, feeding, and overall illness severity. [1][3]
2. Neurologic examination. This looks at muscle tone, reflexes, alertness, movement, and seizure-related findings. [3][4]
3. Developmental assessment. The child’s speech, movement, and learning milestones are compared with normal age expectations. [1][2]
4. Head circumference measurement. This simple exam helps detect microcephaly. [1][2]
5. Eye examination. A detailed eye check can look for visual and structural abnormalities that are common in DPM1-CDG. [1][2]
6. Manual muscle testing. In older infants or children, the examiner can estimate muscle strength by direct bedside testing. [4][7]
7. Tone assessment. The clinician manually moves the arms and legs to detect hypotonia or abnormal resistance. [1][3]
8. Coordination and gait assessment. If the child can sit or walk, the doctor checks balance and coordination for ataxia. [4][11]
9. Serum transferrin isoform analysis. This is a key screening blood test for many CDGs. It looks for an abnormal glycosylation pattern in transferrin. [12][5]
10. Carbohydrate-deficient transferrin pattern testing by isoelectric focusing or similar methods. This helps show a type I CDG pattern, which strongly suggests an early N-glycosylation defect. [12][3]
11. Molecular genetic testing of DPM1. This is the definitive test. Sequencing can identify two pathogenic variants in the DPM1 gene. [12][6]
12. Exome sequencing or multigene panel. These tests are useful when the exact CDG type is not known at first. [12][5]
13. Enzyme or functional studies. In some cases, laboratory studies help confirm that the gene change truly disrupts the glycosylation pathway. [12][6]
14. N-glycan profiling. This specialized test helps separate different CDG subtypes by studying glycan abnormalities. [12]
15. Alpha-dystroglycan analysis. Because DPM1 disease can overlap with dystroglycanopathy-like muscle disease, this test may be helpful in selected cases. [7][9]
16. Creatine kinase blood test. CK may be raised when muscle tissue is affected. [7][8]
17. Liver function tests. Serum transaminases may be elevated, so liver blood tests are often part of the workup. [8][9]
18. Coagulation profile. Clotting studies can detect glycoprotein-related coagulation abnormalities. [3][9]
19. Electroencephalogram, or EEG. EEG helps evaluate seizures and abnormal brain electrical activity. [8]
20. Brain MRI. MRI can look for structural brain changes or other neurologic abnormalities linked with severe glycosylation disease. [8][3]
Carbohydrate-deficient glycoprotein syndrome type Ie is a very rare inherited DPM1-related glycosylation disorder. The main clues are developmental delay, severe motor delay, low muscle tone, seizures, microcephaly, and eye problems, often beginning in infancy. The most important tests are serum transferrin glycosylation testing and genetic testing for DPM1. [1][2][12]
Non-Pharmacological Treatments
1) Early developmental therapy helps the child learn movement, play, attention, and daily skills as early as possible. Purpose: improve overall development. Mechanism: repeated guided practice helps the brain and body use remaining function better. [1][2]
2) Physical therapy is used for low muscle tone, poor balance, delayed walking, and joint stiffness. Purpose: protect strength and mobility. Mechanism: stretching, positioning, balance work, and guided movement reduce secondary weakness and contractures. [1][2]
3) Occupational therapy teaches hand use, posture, feeding support, and daily living skills. Purpose: improve independence. Mechanism: task-based training helps the child practice useful activities again and again. [1]
4) Speech and language therapy can help both communication and swallowing. Purpose: improve speech, safe feeding, and family communication. Mechanism: oral-motor work, language practice, and swallow strategies lower aspiration risk and support interaction. [1][2]
5) Feeding therapy is important when poor suck, slow feeding, choking, or food refusal happens. Purpose: improve calorie intake safely. Mechanism: texture changes, pacing, posture, and swallow training reduce feeding stress. [1][2]
6) High-calorie nutrition planning is often needed because growth failure can occur. Purpose: prevent malnutrition. Mechanism: small frequent feeds, calorie fortification, and close weight checks help meet energy needs. [2][6]
7) Tube feeding support such as nasogastric or gastrostomy feeding may be needed in severe feeding failure. Purpose: secure nutrition and reduce aspiration risk. Mechanism: direct nutrition delivery bypasses tiring or unsafe oral feeding. [1][2]
8) Seizure safety planning includes rescue plans, caregiver training, and emergency steps. Purpose: reduce seizure injury and delays in treatment. Mechanism: fast recognition and action can shorten dangerous seizure events. [1][2]
9) Vision assessment and low-vision support are important because strabismus, nystagmus, and retinopathy may occur. Purpose: protect visual development. Mechanism: early correction and visual support improve function during growth. [1][2]
10) Hearing assessment is reasonable in multisystem CDG care. Purpose: find hidden hearing loss early. Mechanism: hearing support improves language and learning. [1]
11) Mobility aids such as braces, walkers, seating systems, or wheelchairs may help. Purpose: improve safety and comfort. Mechanism: proper support reduces falls, fatigue, and poor posture. [1]
12) Contracture prevention and orthotic care are used when long-term low tone or weakness changes posture. Purpose: keep joints flexible. Mechanism: splints and stretching reduce fixed shortening of muscles and tendons. [1]
13) Constipation management without drugs includes fluids, fiber when tolerated, toilet routine, and abdominal massage. Purpose: improve bowel emptying. Mechanism: regular bowel habits and softer stool reduce pain and feeding intolerance. [6]
14) Reflux precautions include upright feeding, smaller meals, and avoiding lying flat after meals. Purpose: reduce vomiting and aspiration. Mechanism: better positioning lowers backflow from the stomach. [1][6]
15) Skin care matters if dry or ichthyosis-like skin changes appear in some glycosylation disorders. Purpose: protect the skin barrier. Mechanism: regular emollients reduce water loss and cracking. [3]
16) Respiratory care may include suction teaching, airway clearance, and aspiration prevention. Purpose: lower chest infection risk. Mechanism: safer swallowing and secretion management help keep airways clear. [1][2]
17) Cardiology follow-up is useful because some CDG disorders can involve the heart. Purpose: find heart disease early. Mechanism: routine checks such as ECG and echocardiography detect silent problems. [1][7]
18) Immunology review may be needed when infections are frequent or immunoglobulins are low. Purpose: reduce severe infections. Mechanism: targeted immune evaluation helps doctors plan vaccines, prophylaxis, or immune treatment when needed. [1]
19) Family genetic counseling explains inheritance, testing of relatives, and future pregnancy options. Purpose: improve informed decisions. Mechanism: clear risk information supports planning and earlier diagnosis. [1][4]
20) Long-term multidisciplinary follow-up is one of the most important therapies. Purpose: catch new problems early. Mechanism: regular review of growth, development, eyes, nerves, gut, liver, clotting, and heart helps prevent complications. [1][3]
Drug Treatments
Important: these drugs treat symptoms, not the root DPM1 defect. Use only under a doctor’s care. [4][5]
1) Levetiracetam is an anti-seizure drug often used when seizures are present. Class: antiepileptic. Dose: individualized by age and weight. Time: usually daily. Purpose: seizure control. Mechanism: helps stabilize abnormal nerve firing. Common side effects: sleepiness, irritability, dizziness. [8]
2) Clonazepam may be used for some seizure types. Class: benzodiazepine antiepileptic. Dose: specialist-guided. Time: usually divided dosing. Purpose: lower seizure frequency. Mechanism: increases inhibitory GABA signaling. Side effects: sedation, drooling, poor coordination, dependence risk. [9]
3) Diazepam rectal gel may be kept as a rescue medicine for prolonged seizures. Class: benzodiazepine rescue drug. Purpose: stop a seizure emergency outside hospital. Mechanism: rapid GABA enhancement. Side effects: sleepiness, slowed breathing, weakness. [10]
4) Phenobarbital is sometimes used in infant seizures. Class: barbiturate antiepileptic. Purpose: reduce severe seizures. Mechanism: increases inhibitory brain signaling. Side effects: sedation, breathing suppression, feeding trouble, slow development with long use. [11]
5) Baclofen can help spasticity or painful muscle tightness if that develops. Class: antispasticity drug. Purpose: improve comfort and movement. Mechanism: acts on GABA-B pathways in the spinal cord. Side effects: weakness, sleepiness, dizziness, constipation. [12]
6) Diazepam oral may also be used for spasticity in selected patients. Class: benzodiazepine. Purpose: reduce muscle spasm and stiffness. Mechanism: central muscle relaxation through GABA. Side effects: sedation, falls, dependence, breathing risk. [13]
7) Gabapentin may help neuropathic pain or irritability linked to nerve discomfort. Class: anticonvulsant/neuropathic pain agent. Purpose: improve comfort. Mechanism: reduces excitatory nerve signaling. Side effects: sleepiness, dizziness, swelling. [14]
8) Omeprazole is used when reflux is strong. Class: proton pump inhibitor. Purpose: lower acid and reduce esophageal irritation. Mechanism: blocks the acid pump in the stomach. Side effects: diarrhea, headache, abdominal pain. [15]
9) Ondansetron may be used when nausea and vomiting are severe. Class: 5-HT3 blocker. Purpose: reduce vomiting. Mechanism: blocks serotonin-triggered nausea pathways. Side effects: constipation, headache, QT prolongation risk. [16]
10) Polyethylene glycol is often used for constipation. Class: osmotic laxative. Purpose: soften stool. Mechanism: pulls water into the bowel. Side effects: bloating, loose stool, cramps. [17]
11) Acetaminophen may be used for fever or pain. Class: analgesic/antipyretic. Purpose: comfort and fever control. Mechanism: central pain and temperature effect. Side effects: liver injury in overdose. [18]
12) Albuterol can help wheeze or reactive airway symptoms during respiratory illness. Class: beta-2 bronchodilator. Purpose: open airways. Mechanism: relaxes bronchial smooth muscle. Side effects: tremor, fast heart rate, nervousness. [19]
13) Calcitriol may be used only if a doctor finds vitamin D-related bone or calcium problems. Class: active vitamin D analog. Purpose: support calcium balance. Mechanism: increases intestinal calcium absorption. Side effects: high calcium, kidney stones, vomiting. [20]
14) Broad-spectrum antibiotics are used only for proven bacterial infection. Purpose: treat pneumonia, sepsis, or severe chest infection. Mechanism: kill or block growth of bacteria. Side effects: diarrhea, rash, resistance risk. In DPM1-CDG, infection treatment can be life-saving. [1][21]
15) Topical emollient barrier products are useful when skin is dry or cracked. Class: skin protectants. Purpose: reduce discomfort and infection entry. Mechanism: restore the skin barrier and hold moisture. Side effects: local irritation is uncommon. [3]
16) Artificial tears or ocular lubricants may help exposure or surface irritation in eye involvement. Purpose: protect the cornea. Mechanism: keep the eye surface moist. Side effects: mild temporary blur. [1][2]
17) Nutritional formulas are “medical nutrition” rather than true curative drugs, but they are often essential in care. Purpose: maintain growth. Mechanism: deliver calories, protein, and micronutrients more reliably. [6]
18) Rescue hydration solutions may be needed during vomiting or diarrhea. Purpose: prevent dehydration. Mechanism: replace water and salts. [6]
19) IVIG or other immune therapy may be considered only when a specialist documents significant antibody deficiency or recurrent severe infections. Evidence in DPM1-CDG is limited, so this is individualized, not routine. [1]
20) Experimental CDG-directed therapy is still research-stage. Reviews note that most CDGs still lack a cure, and newer glycosylation-targeted therapies are under study rather than standard care for DPM1-CDG today. [4][5][22]
Dietary Molecular Supplements
1) Standard multivitamin/mineral support may help when intake is poor. Dose: age-based. Function: fills common gaps. Mechanism: supports many body enzymes and growth processes. [6]
2) Vitamin D may be used if deficiency risk is high. Function: bone health. Mechanism: improves calcium absorption and bone mineral use. [20]
3) Calcium may be added when intake is low. Function: bone and muscle support. Mechanism: provides the mineral needed for bone structure and nerve-muscle signaling. [20]
4) Iron is used only if iron deficiency is proven. Function: supports red blood cell production. Mechanism: helps hemoglobin carry oxygen. [6]
5) Zinc may help if deficiency or poor growth is present. Function: immune and skin support. Mechanism: supports enzymes, repair, and appetite. [6]
6) Omega-3 fatty acids may support general nutrition when diet is limited. Function: calorie and membrane support. Mechanism: adds essential fats needed for growth and cell membranes. [6]
7) Protein modular supplements can be added to feeds in failure to thrive. Function: support growth and tissue repair. Mechanism: increase protein intake without large meal volume. [6]
8) Fiber supplements may help constipation in selected patients who can tolerate them. Function: bowel support. Mechanism: improve stool bulk and regularity. [6]
9) Oral rehydration salts support fluid and electrolyte balance during illness. Function: prevent dehydration. Mechanism: sodium-glucose transport improves water uptake in the gut. [6]
10) Specialized high-calorie formulas are often more useful than disease-specific supplements because undernutrition is common. Function: growth support. Mechanism: provide dense calories in small volumes. [1][6]
Immunity, Regenerative, or Stem Cell Drug Options
At present, no FDA-approved regenerative or stem cell drug is established for DPM1-CDG itself. The safest evidence-based statement is that these approaches remain experimental or individualized supportive care, not standard therapy. [4][5]
1) IVIG may sometimes be used in selected patients with documented antibody deficiency. [1]
2) Vaccine optimization plans are preventive, not regenerative, but important when infections are frequent. [1]
3) Nutritional rehabilitation is supportive, not stem cell therapy, yet often gives the biggest practical benefit. [6]
4) Gene-targeted or substrate-targeted therapies are under research in broader CDG programs, not established for routine DPM1-CDG care. [22]
5) Precision-medicine trials may become relevant in the future through rare disease centers. [23]
6) Stem cell treatment is not standard of care for DPM1-CDG today. [4][5]
Surgeries or Procedures
1) Gastrostomy tube placement may be done for long-term unsafe feeding or severe growth failure. Why: improve nutrition and reduce aspiration. [1][2]
2) Nasogastric tube placement is a less invasive feeding procedure used earlier. Why: temporary nutritional rescue. [1]
3) Strabismus surgery may be needed in selected eye cases. Why: improve eye alignment and sometimes function. [1][2]
4) Orthopedic procedures may rarely be needed for severe contractures, hip issues, or deformity from long-term motor problems. Why: improve pain, positioning, and care. [1]
5) Central line or hospital intensive procedures may be required during severe infection or seizures. Why: emergency stabilization, not disease cure. [21]
Prevention Tips
Good prevention in DPM1-CDG means preventing complications, not preventing the gene disorder itself. [1][4]
- Keep regular metabolic and neurology follow-up. [1]
- Track weight, length, and head growth carefully. [1][2]
- Treat seizures early and keep a rescue plan ready. [1]
- Use swallow evaluation when choking or coughing with feeds appears. [1]
- Prevent dehydration during vomiting, fever, or diarrhea. [6]
- Keep vaccines and infection prevention up to date. [1]
- Check vision and hearing early. [1][2]
- Use physical therapy and positioning to prevent contractures. [1]
- Screen heart, liver, and clotting issues when advised. [1][7]
- Seek genetic counseling before future pregnancy planning. [1][4]
When to see doctors
See a doctor urgently for a first seizure, a seizure lasting more than a few minutes, blue color, repeated vomiting, poor feeding, dehydration, breathing trouble, fever with weakness, reduced urine, unusual sleepiness, or any sudden loss of skills. Routine review is also needed for poor growth, eye changes, repeated infections, constipation, reflux, pain, or new movement problems. [1][2][21]
What to eat and what to avoid
Eat or use more often: calorie-dense feeds, enough protein, safe textures, fluids, doctor-guided vitamin D or minerals when deficient, and specialized formulas if growth is poor. Avoid or limit: unsafe thin liquids if aspiration is present, long gaps without feeding, foods that worsen reflux, dehydration, and any supplement marketed as a “cure” without specialist approval. No special universal CDG-Ie diet has been proven to cure the disorder; nutrition is personalized around growth, tolerance, swallowing, and gut symptoms. [6][4]
FAQs
1) Is CDG-Ie the same as DPM1-CDG? Yes. CDG-Ie is the older name. [1][2]
2) Is it genetic? Yes, it is inherited and usually autosomal recessive. [1][4]
3) Can it be cured? No proven cure is available yet. [4][5]
4) Is there a disease-specific FDA-approved drug? Not for DPM1-CDG at present. Care is supportive. [4][5]
5) Are seizures common? Yes, seizures are a major reported feature. [1][2]
6) Can feeding be difficult? Yes, some children have severe feeding and gastrointestinal problems. [1][2]
7) Can eyes be affected? Yes, strabismus, nystagmus, and retinopathy may occur. [1][2]
8) Does every child look the same? No, severity varies a lot. [2][3]
9) Is developmental delay common? Yes, it is one of the core features. [1][2]
10) Can infection be serious? Yes, severe infection has been reported in some cases. [21]
11) Is physiotherapy helpful? Yes, it helps function and complication prevention. [1]
12) Can tube feeding help? Yes, when oral feeding is unsafe or not enough. [1]
13) Should siblings be tested? Families should discuss this with a genetics team. [1][4]
14) Are research trials happening? Yes, broader CDG research and natural history studies are ongoing. [23]
15) What helps most right now? Early diagnosis, nutrition support, seizure control, therapy, and regular specialist follow-up help the most. [1][6]
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 31, 2025.
